Hologic (NASDAQ:HOLX) had its target price hoisted by investment analysts at Raymond James from $68.00 to $78.00 in a note issued to investors on Thursday, BenzingaRatingsTable reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Raymond James’ price target would indicate a potential upside of 11.78% from the company’s current price.

Several other research analysts have also recently issued reports on HOLX. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $64.00 price objective for the company in a research report on Tuesday, June 30th. Needham & Company LLC boosted their target price on Hologic from $64.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday. SVB Leerink boosted their target price on Hologic from $66.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday. Wells Fargo & Co boosted their target price on Hologic from $48.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, JPMorgan Chase & Co. boosted their target price on Hologic from $45.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $64.28.

Hologic stock traded up $0.07 during midday trading on Thursday, hitting $69.78. 2,584,378 shares of the company were exchanged, compared to its average volume of 1,982,671. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.04 and a current ratio of 1.47. Hologic has a fifty-two week low of $26.49 and a fifty-two week high of $70.35. The business has a fifty day simple moving average of $57.42 and a two-hundred day simple moving average of $50.06. The firm has a market capitalization of $18.05 billion, a PE ratio of 28.25, a price-to-earnings-growth ratio of 3.69 and a beta of 1.47.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.37. Hologic had a return on equity of 31.40% and a net margin of 20.03%. The company had revenue of $822.90 million for the quarter, compared to the consensus estimate of $622.96 million. During the same quarter in the previous year, the business earned $0.63 earnings per share. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. As a group, equities analysts expect that Hologic will post 2.3 earnings per share for the current year.

In other news, insider Peter J. Valenti III sold 10,493 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $51.82, for a total transaction of $543,747.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 190,996 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total value of $9,735,066.12. The disclosure for this sale can be found here. Insiders sold 243,932 shares of company stock worth $12,507,250 over the last three months. 1.00% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Baird Financial Group Inc. grew its stake in shares of Hologic by 1.7% during the first quarter. Baird Financial Group Inc. now owns 14,831 shares of the medical equipment provider’s stock valued at $521,000 after acquiring an additional 242 shares in the last quarter. Cornerstone Advisors Inc. grew its stake in shares of Hologic by 202.0% during the second quarter. Cornerstone Advisors Inc. now owns 447 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 299 shares in the last quarter. Signaturefd LLC grew its stake in Hologic by 37.8% in the second quarter. Signaturefd LLC now owns 1,091 shares of the medical equipment provider’s stock worth $62,000 after purchasing an additional 299 shares in the last quarter. CWM LLC grew its stake in Hologic by 63.4% in the first quarter. CWM LLC now owns 910 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 353 shares in the last quarter. Finally, CIBC Asset Management Inc grew its stake in Hologic by 1.7% in the second quarter. CIBC Asset Management Inc now owns 22,734 shares of the medical equipment provider’s stock worth $1,296,000 after purchasing an additional 381 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: What kind of dividend yield to CEF’s pay?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.